View in EDS

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond.

Saved in:
Bibliographic Details
Title: Immunotherapy for Stage III NSCLC: Durvalumab and Beyond.
Authors: Fitzpatrick O; Department of Oncology, Beaumont Hospital, RCSI University of Health Sciences, Dublin, Ireland., Naidoo J; Department of Oncology, Beaumont Hospital, RCSI University of Health Sciences, Dublin, Ireland.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, 21231, USA.
Source: Lung Cancer (Auckland, N.Z.) [Lung Cancer (Auckl)] 2021 Nov 02; Vol. 12, pp. 123-131. Date of Electronic Publication: 2021 Nov 02 (Print Publication: 2021).
Publication Type: Journal Article; Review
Journal Info: Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101632521 Publication Model: eCollection Cited Medium: Print ISSN: 1179-2728 (Print) Linking ISSN: 11792728 NLM ISO Abbreviation: Lung Cancer (Auckl) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34754256
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Immunotherapy for Stage III NSCLC: Durvalumab and Beyond.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Fitzpatrick+O%22">Fitzpatrick O</searchLink>; Department of Oncology, Beaumont Hospital, RCSI University of Health Sciences, Dublin, Ireland.<br /><searchLink fieldCode="AU" term="%22Naidoo+J%22">Naidoo J</searchLink>; Department of Oncology, Beaumont Hospital, RCSI University of Health Sciences, Dublin, Ireland.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, 21231, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101632521%22">Lung Cancer (Auckland, N.Z.)</searchLink> [Lung Cancer (Auckl)] 2021 Nov 02; Vol. 12, pp. 123-131. <i>Date of Electronic Publication: </i>2021 Nov 02 (<i>Print Publication: </i>2021).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Dove+Medical+Press%22">Dove Medical Press </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>101632521 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1179-2728 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2211792728%22">11792728 </searchLink><i>NLM ISO Abbreviation: </i>Lung Cancer (Auckl) <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34754256
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2147/LCTT.S305466
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 123
    Titles:
      – TitleFull: Immunotherapy for Stage III NSCLC: Durvalumab and Beyond.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fitzpatrick O
      – PersonEntity:
          Name:
            NameFull: Naidoo J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 11
              Text: 2021 Nov 02
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 1179-2728
          Numbering:
            – Type: volume
              Value: 12
          Titles:
            – TitleFull: Lung Cancer (Auckland, N.Z.)
              Type: main
ResultId 1